Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down

Summary

Eli Lilly has become a dominant force in biotech M&A during the first half of 2026, leveraging its trillion-dollar market capitalization and success in obesity treatment. The company shows no signs of slowing its acquisition activity.